logo
JPMorgan moves further into crypto with stablecoin-like token JPMD

JPMorgan moves further into crypto with stablecoin-like token JPMD

CNBC6 hours ago

JPMorgan Chase is taking a step further into the cryptocurrency space with its own stablecoin-like token, called JPMD.
The U.S. banking giant told CNBC on Tuesday that it's planning to launch a so-called deposit token on Coinbase's public blockchain Base, which is built on top of the Ethereum network. Each deposit token is meant to serve as a digital representation of a commercial bank deposit.
JPMD will offer clients round-the-clock settlement as well as the ability to pay interest to holders. It is a so-called "permissioned token," meaning it is only available to JPMorgan's institutional clients — unlike many stablecoins, which are publicly available.
"We see institutions using JPMD for onchain digital asset settlement solutions as well as for making cross-border business-to-business transactions," Naveen Mallela, global co-head of Kinexys, J.P. Morgan's blockchain unit, told CNBC Tuesday.
"Given the fact that deposit tokens would eventually be interest bearing as well, this would provide better fungibility with existing deposit products that institutions currently use," he added.
JPMorgan said the benefit of launching a deposit token over a stablecoin is that it gives institutional clients a way to move money around faster and easier while still having a close connection with traditional banking systems.
A stablecoin is a type of digital token that's designed to be pegged 1:1 to the value of a fiat currency at all times. The most popular stablecoins are Tether's USDT and Circle's USDC. The entire stablecoin market is worth approximately $262 billion, according to data from CoinGecko.
In the U.S., stablecoins remain broadly unregulated — although this is likely to change soon. The Senate is set to vote Tuesday on the GENIUS Act, legislation that would introduce formal regulation for such tokens.
Elsewhere, the European Union regulates stablecoins under its Markets in Crypto-Assets Regulation, or MiCA, while the U.K. has also laid out plans to regulate the crypto industry. Britain's Financial Conduct Authority is currently consulting on proposals to require stablecoin issuers to ensure their tokens maintain their value against a given asset.
JPMorgan's digital asset chief told CNBC that the bank chose Coinbase as its blockchain partner since the crypto exchange is already a long-standing client and a leader in the crypto space.
JPMD has had "preliminary interest from large institutional players who want more native onchain cash solutions from pre-eminent and reputed financial institutions," Mallela added.
Speculation had been building around JPMorgan's new crypto offering after a trademark application filed by the bank for "JPMD" was made public Monday.
The trademark outlined a broad range of crypto services under the JPMD name, including trading, exchange, transfer and payment services for digital assets.
Various crypto media outlets had speculated whether the bank was about to launch its own stablecoin. However, JPMorgan says that, while its token may share some similarities with a stablecoin, it's ultimately a different kind of product.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Coinbase wants SEC to greenlight tokenized stock trading
Coinbase wants SEC to greenlight tokenized stock trading

Yahoo

time33 minutes ago

  • Yahoo

Coinbase wants SEC to greenlight tokenized stock trading

Coinbase wants SEC to greenlight tokenized stock trading originally appeared on TheStreet. Coinbase (Nasdaq: COIN), the largest U.S. crypto exchange, is seeking regulatory authority from the Securities and Exchange Commission (SEC) to offer tokenized equities, a move that could position it to compete with Robinhood and Charles Schwab. Coinbase's Chief Legal Officer, Paul Grewal, said in a Reuters interview that the concept is a "huge priority." Tokenized equities means taking a traditional share of a company and converting it into digital tokens that are traded on the blockchain. Advocates argue that this reduces brokerage fees, speeds up settlements, and enables individuals to trade 24/7. But there are obstacles. At present, tokenized equities cannot be traded in the United States. Competitor exchange Kraken has recently rolled out "xStocks" outside the U.S., which provides a snapshot of future trading possibilities for tokenized stocks worldwide. To proceed in a U.S. environment, Coinbase would require a "no-action letter" or "exemptive relief" from the SEC, essentially guaranteeing that the company would not be subject to enforcement action if it pursued these types of transactions. Grewal would not confirm whether Coinbase had submitted a formal request but said that institutions have been hesitant as a result of the lack of guidance presently. Coinbase currently holds a broker-dealer license from a company it acquired in 2018, but that entity is no longer active. The request comes against the backdrop of a broader shift in U.S. crypto policy under President Donald Trump, under whose tenure the SEC has abandoned its legal cases against key exchanges. If granted, this could create a new and massive source of revenue for Coinbase, entirely redefining retail investing. Coinbase's stock is trading at $250.02 at press time, down over 4.55% in the last 24 hours. Coinbase wants SEC to greenlight tokenized stock trading first appeared on TheStreet on Jun 17, 2025 This story was originally reported by TheStreet on Jun 17, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

JPMorgan Introduces USD Deposit Token on Coinbase's Base Blockchain
JPMorgan Introduces USD Deposit Token on Coinbase's Base Blockchain

Yahoo

time33 minutes ago

  • Yahoo

JPMorgan Introduces USD Deposit Token on Coinbase's Base Blockchain

U.S. banking giant JPMorgan has announced the pilot of a permissioned USD deposit token called JPMD on Base, the layer 2 Ethereum network built by listed exchange Coinbase (COIN). Earlier this week, the bank filed a trademark application for a crypto-focused platform named JPMD, designed to to offer services such as trading, exchange, transfer, and payment services for digital assets, as well as issuance of digital assets. The institution-focused JPMD, an alternative to stablecoins for the bank's clients, marks the first deployment of JPMorgan's Kinexys distributed ledger technology studio on a public blockchain, according to a press release. Banks and other enterprise players are crowding into the stablecoin space ahead of soon-to-land rules around dollar-pegged tokens in the U.S. JPMorgan garnered lots of attention for its so-called JPM Coin, a token for settling the cash leg of trades on its private blockchain, then called Onyx Digital Assets. 'We are thrilled to see one of the world's most prominent banks come onchain,' said Jesse Pollak, Creator of Base and VP of Engineering at Coinbase. 'Base offers sub-second, sub-cent, 24/7 settlement, which makes fund transfers between J.P. Morgan institutional clients nearly instant. Coinbase is a proud J.P. Morgan institutional client, and this pilot combines the credibility of both J.P. Morgan and Base to help bring institutional money into a more global economy.'

Investors flock to Chinese herbal medicine stock with no revenues
Investors flock to Chinese herbal medicine stock with no revenues

UPI

timean hour ago

  • UPI

Investors flock to Chinese herbal medicine stock with no revenues

Regencell Bioscience Holdings' NASDAQ stock price rallied with a 280% increase on Monday and another 25% on Tuesday after a recent 38-for-1 stock split took effect on Thursday. File Photo by Angelina Katsanis/UPI | License Photo June 17 (UPI) -- Shares in Hong Kong-based Regencell Bioscience Holdings nearly quadrupled in value amid a 38-to-1 stock split despite the firm reporting no revenues. The stock split triggered a 280% share price increase on Monday, CNBC reported, and continued a 58,000% increase in its price in 2025, with a closing cost of $78 per share on the NASDAQ trading platform on Tuesday. The stock reached a high of $81.23 during morning trading and slumped slightly to $75.47 during Tuesday's after-hours trading. The stock is rated as a "buy" on the TipRanks website after Regencell officials on June 2 announced the stock split to improve its liquidity and value for shareholders. The stock split gave investors 37 shares for each share held on June 12. The shares began trading on a split-adjusted basis on Monday, according to Seeking Alpha. The firm has no reported revenue but says it is developing a Chinese herbal treatment for childhood attention deficit hyperactivity disorder and autism. The firm was established in 2014 and has been traded on NASDAQ under the RGC symbol since 202. It had a market capitalization of $29.7 billion at the end of trading on Monday. The market capitalization rose another 25% on Tuesday, with a total value of $36 billion. The stock traded for pennies per share last year but now has a greater market value than highly recognized businesses, including Kraft Heinz, Lululemon and eBay, according to CNBC. Part of the increased investor interest is due to Health and Human Services Secretary Robert Kennedy Jr. raising awareness of alternative medicines. Regencell Chief Executive Officer Yat-Gai Au controls more than 86% of the company's outstanding shares, according to FactSet. Little information is available about the potential effectiveness of the company's claims regarding its three traditional Chinese medicine formulas that are supposed to treat mild to severe forms of ADHD and autism with natural herbal medications in liquid form. Company officials in October reported no generated revenue and no regulatory approvals for its three liquid medicines. They reported net losses of $6.06 million in 2023 and $4.36 million in 2024. A Regencell patient case study in late 2023 said 28 patients were treated over three months during a second trial, which showed improvements in ADHD and autism. A dozen patients participated in a 2021 study to treat COVID-19, which indicated improvement in their symptoms.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store